Editorials Selegiline in Parkinson's disease BMJ 1995; 311 doi: https://doi.org/10.1136/bmj.311.7020.1583 (Published 16 December 1995) Cite this as: BMJ 1995;311:1583 Article Related content Metrics Responses Peer review Related articles No related articles found. See more Thiazide diuretics seem to protect against fracture BMJ November 22, 2016, 355 i6263; DOI: https://doi.org/10.1136/bmj.i6263 Steroid injections through the eardrum reduce dizziness in Meniere’s disease, study finds BMJ November 18, 2016, 355 i6185; DOI: https://doi.org/10.1136/bmj.i6185 Chronic insomnia: diagnosis and non-pharmacological management BMJ November 16, 2016, 355 i5819; DOI: https://doi.org/10.1136/bmj.i5819 Risks of duloxetine for stress incontinence outweigh benefits, say researchers BMJ November 15, 2016, 355 i6103; DOI: https://doi.org/10.1136/bmj.i6103 How changes to drug prohibition could be good for the UK—an essay by Molly Meacher and Nick Clegg BMJ November 14, 2016, 355 i6006; DOI: https://doi.org/10.1136/bmj.i6006 Cited by... Glyceraldehyde-3-phosphate Dehydrogenase, the Putative Target of the Antiapoptotic Compounds CGP 3466 andR-(-)-DeprenylAbstract Fulltext PDF Unexpected findings of study of selegiline have not been treated with caution its authors advisedAbstract Fulltext PDF Selegiline may be toxic in presence of increased dopamine concentrationsAbstract Fulltext PDF Parkinson's disease is rarely a primary cause of deathAbstract Fulltext PDF Patients taking selegiline may have received more levodopa than necessaryAbstract Fulltext PDF Stopping selegiline may lead to problems for patientsAbstract Fulltext PDF
